Melatonin for Dogs: Dosing, Safety, and When It Helps

What melatonin does in your dog's body

Your dog's pineal gland produces melatonin naturally. The synthesis pathway starts with tryptophan, converts it to serotonin, then to N-acetylserotonin, and finally to melatonin — a cascade triggered by darkness and suppressed by light exposure. In dogs, as in other mammals, this endogenous melatonin secretion follows a circadian pattern: levels rise in the evening, peak during the night, and decline toward morning (PMCID: PMC11833209).

That circadian role is melatonin's primary biological function — synchronizing the sleep-wake cycle with the light-dark environment. But melatonin also acts on multiple receptor subtypes (MT1 and MT2) distributed across the brain, and those receptors influence more than just sleep onset. The same 2025 behavioral review noted that melatonin modulates stress response pathways, interacts with GABAergic neurotransmission, and may reduce hypothalamic-pituitary-adrenal (HPA) axis activation — the hormonal cascade responsible for cortisol release during acute stress.

This dual role — circadian regulator and stress modulator — is why veterinarians reach for melatonin in anxiety contexts. It is not a sedative in the conventional pharmacological sense. Instead, it shifts the nervous system toward a state that is more compatible with rest and less reactive to stressors. The distinction matters: a sedated dog is cognitively suppressed, while a dog under melatonin's influence is physiologically primed for calm without losing alertness entirely.

The evidence for anxiety use

Melatonin occupies an unusual position in canine behavioral pharmacology: it is one of the most frequently prescribed over-the-counter calming agents, yet the direct behavioral trial evidence in dogs is thinner than that clinical prevalence suggests. A 2022 review of melatonin as a functional ingredient in dogs (PMCID: PMC9405278) characterized it as having anxiolytic and calming properties, noting its common veterinary use for nervousness and noise phobia, while also acknowledging that the supporting data derives partly from mammalian models rather than exclusively from controlled canine behavioral trials.

Where the evidence is strongest is in the broader behavioral literature. A 2025 cross-species review (PMCID: PMC11833209) documented melatonin's association with reduced anxiety, lower stress reactivity, and improved adaptation to environmental disruptions across multiple mammalian species. The mechanism is pharmacologically plausible: melatonin interacts with GABA receptors (the same target as benzodiazepines, though through a different binding mechanism), attenuates cortisol release, and reduces sympathetic nervous system activation.

For noise phobia specifically, a 2023 practitioner review of noise fear therapies (PMCID: PMC10705068) included melatonin among recommended pharmacological interventions, typically administered 30 to 60 minutes before a predicted noise event. That same review positioned melatonin as a lower-risk option compared to prescription anxiolytics like benzodiazepines or trazodone, with the trade-off being a milder effect ceiling. Melatonin is also referenced in pre-veterinary-visit protocols (PMCID: PMC8360309) as one component of multi-drug anxiolytic regimens for dogs with veterinary-visit fear.

The honest summary: melatonin has a plausible mechanism, broad clinical use, and supporting mammalian evidence — but fewer large-scale, randomized controlled trials specific to canine anxiety than some other calming supplement categories. Compared to the other calming supplement categories, melatonin's advantage is a relatively well-understood mechanism and a long track record of clinical use with few reported adverse effects. Its limitation is the same as most canine nutraceuticals: the behavioral evidence lags behind the prescribing frequency.

Dosing: what veterinary guidance looks like

Melatonin dosing in dogs varies by body weight, the target condition, and individual response. Published veterinary references (PMCID: PMC9405278) cite ranges from approximately 0.1 mg/kg for lower-end applications up to 1.0–1.7 mg/kg for conditions like seasonal flank alopecia. For anxiety and behavioral use, veterinary protocols typically fall in the lower portion of that range.

Ask your veterinarian for your dog's specific dose. In practice, veterinarians often prescribe by size bracket rather than precise per-kilogram calculation. Commonly cited ranges in veterinary references for anxiety use are approximately 1 mg for dogs under 10 pounds, 1.5–3 mg for dogs between 10 and 50 pounds, and 3–6 mg for dogs over 50 pounds — though individual dogs may require adjustment within or outside those ranges depending on the condition, concurrent medications, and clinical response. These are reference ranges, not prescriptions.

The xylitol problem

This is the single most dangerous aspect of melatonin supplementation in dogs, and it has nothing to do with melatonin itself.

Xylitol (also labeled as birch sugar or “sugar alcohol”) is an artificial sweetener used in many human chewable tablets and gummies, including some melatonin products sold for human consumption. In humans, xylitol is benign. In dogs, it triggers a rapid, massive insulin release that can cause life-threatening hypoglycemia within 10 to 60 minutes of ingestion. At higher doses, xylitol has been associated with acute hepatic necrosis — a case report (PMCID: PMC4880608) documented fatal liver failure in a dog following xylitol ingestion.

The risk is not theoretical. A documented case (PMCID: PMC6332764) reported simultaneous xylitol toxicosis and serotonin syndrome in a dog after ingesting a single human supplement product — demonstrating that human-formulated supplements can contain multiple ingredients that are toxic to dogs in a single tablet.

The safest path is a veterinary-formulated melatonin product designed for dogs, where the excipient and sweetener profiles are chosen with canine safety in mind. If cost or availability pushes you toward a human product, confirm with your veterinarian that every ingredient — active and inactive — is safe for your dog's species and size.

Safety profile and contraindications

Among calming supplements, melatonin has one of the more favorable safety profiles in published veterinary literature. A 2019 study (PMCID: PMC6858660) administered melatonin at 0.3 mg/kg daily in dogs and found no adverse effects on hepatic enzymes (ALT, AST, ALP) or renal markers (BUN, creatinine). The same study observed that melatonin actually increased antioxidant enzyme activity (glutathione peroxidase, superoxide dismutase, catalase) while decreasing oxidative stress markers — suggesting a protective rather than harmful metabolic effect at that dose.

A 2022 review of melatonin in dogs (PMCID: PMC9405278) noted that the lack of secondary effects is what often makes melatonin preferable to prescription sedatives or tranquilizers in clinical practice. The reported side effects are mild and infrequent: occasional gastrointestinal upset, transient drowsiness (expected, given the mechanism), and rare instances of tachycardia or itching.

Choosing a melatonin product

Not all melatonin products are equivalent, and the label differences matter more for dogs than they do for humans. The primary selection criteria are ingredient safety (no xylitol, no undisclosed excipients), appropriate dosing granularity for your dog's weight, and formulation quality.

Our calming supplements overview covers the full range of ingredient categories and how they compare across evidence quality, onset timing, and anxiety-type fit.

Frequently asked questions